Now Reading: Leqembi launched in India for early Alzheimer’s after CDSCO approval
-
01
Leqembi launched in India for early Alzheimer’s after CDSCO approval
Eisai has launched Leqembi, or lecanemab, in India for patients with mild cognitive impairment and mild dementia caused by early Alzheimer’s disease, after receiving marketing authorisation from the Central Drugs Standard Control…
The Story in Brief
Eisai has launched Leqembi, or lecanemab, in India for patients with mild cognitive impairment and mild dementia caused by early Alzheimer’s disease, after receiving marketing authorisation from the Central Drugs Standard Control Organisation. The company describes it as India’s first disease-modifying therapy for the condition.
Patients must first undergo testing for amyloid pathology through cerebrospinal fluid or serum biomarkers. Eisai said access could be limited by the cost of treatment, gaps in early diagnosis, biomarker testing, infusion facilities and reimbursement. Estimates cited from the AIIMS-USC LASI study put India’s dementia burden among people aged 60 and above at 8.8 million in 2023, with the number projected to nearly double by 2036.
The Indian Opinion
The claim that a new drug will transform Alzheimer’s care risks outrunning India’s health system. Equally, dismissing it as inaccessible ignores the need to test whether structured support programmes can reach suitable patients. The practical measure will be uptake among biomarker-confirmed patients, alongside clear reporting of treatment access and affordability over the next few years.
Source: thehindu.com
This story was synthesised by AI from the source linked above.
